Cognitive function · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of MCI · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of dementia · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (Hypoglycaemia) · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Live birth rate per woman · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin showed no clear difference in live birth rate per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review
Live birth rate per woman aParticipants with BMI < 30 kg/m2 or ≤ 32 kg/m2 · women with polycystic ovary syndrome
It is very uncertain whether metformin changes live birth rate per woman Participants with BMI < 30 kg/m2 or ≤ 32… compared with clomiphene citrate (very low certainty).
Live birth rate per woman aParticipants with BMI ≥ 30 kg/m2 · women with polycystic ovary syndrome
It is very uncertain whether metformin changes live birth rate per woman Participants with BMI ≥ 30 kg/m2a compared with clomiphene citrate (very low certainty).
Gastrointestinal adverse events · women with polycystic ovary syndrome
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
Clinical pregnancy rate per woman Participants with BMI < 30 kg/m2 or ≤ 32 kg/m2a · women with polycystic ovary syndrome
It is very uncertain whether metformin changes clinical pregnancy rate per woman Participants with BMI < 30 kg/m2… compared with clomiphene citrate (very low certainty).
Clinical pregnancy rate per woman aParticipants with BMI ≥ 30 kg/m2 · women with polycystic ovary syndrome
It is very uncertain whether metformin changes clinical pregnancy rate per woman Participants with BMI ≥ 30 kg/m2a compared with clomiphene citrate (very low certainty).
Menstrual frequency per woman · women with polycystic ovary syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ovulation rate per woman fParticipants with BMI < 30 kg/m2 · women with polycystic ovary syndrome
Metformin showed no clear difference in ovulation rate per woman Participants with BMI < 30 kg/m2b compared with clomiphene citrate (low certainty).
Gastrointestinal adverse events · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin probably leads to higher adverse events (gastrointestinal) per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Ovulation rate per woman fParticipants with BMI ≥ 30 kg/m2 · women with polycystic ovary syndrome
Metformin may leads to lower ovulation rate per woman Participants with BMI ≥ 30 kg/m2b compared with clomiphene citrate (low certainty).
Miscarriage · women with polycystic ovary syndrome
It is very uncertain whether metformin changes miscarriage rate per woman compared with clomiphene citrate (very low certainty).
1 finding from 1 review
Clinical pregnancy rate · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin probably leads to higher clinical pregnancy rate per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Menstrual frequency per woman · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin may leads to higher menstrual frequency per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review
Ovulation rate · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin probably leads to higher ovulation rate per woman compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Miscarriage · Women with polycystic ovary syndrome, oligo amenorrhoea and subfertility
Metformin showed no clear difference in miscarriage rate per woman compared with placebo or no treatment (low certainty).
1 finding from 1 review